Berkeley Heights, NJ - September 18, 2003
A live audio webcast of the presentation can be accessed through
Genta's Investor Relations site at:
http://www.genta.com/genta/InvestorRelation/events.html
. A replay will be available for 30 days following and will begin
24 hours after the presentation.
About Genta
Genta Incorporated is a biopharmaceutical company with a
diversified product portfolio that is focused on delivering
innovative products for the treatment of patients with cancer. The
Company's research platform is anchored by two major programs that
center on DNA/RNAbased medicines and small molecules. Genasense
TM
(oblimersen sodium) is the Company's lead compound from its
oligonucleotide program and is currently undergoing late-stage,
Phase 3 clinical testing. The leading drug in Genta's small
molecule program is Ganite
TM
(gallium nitrate injection), which under today's approval from the
FDA, will be marketed for the treatment of cancer-related
hypercalcemia that is resistant to hydration. For more information
about Genta, please visit our website at:
http://www.genta.com/
.
This press release and the webcast to follow contain
forward-looking statements with respect to business conducted by
Genta Incorporated. By their nature, forward-looking statements
and forecasts involve risks and uncertainties because they relate
to events and depend on circumstances that will occur in the
future. There are a number of factors that could cause actual
results and developments to differ materially. For a discussion
of those risks and uncertainties, please see the Company's Annual
Report/Form 10-K
for 2002.
SOURCE: Genta Incorporated
